The Schechter and Berger nomenclature

FIG. 1






FIG. 2






.

FIG. 4A


FIG. 4F

Ac-PRNK-ACC as an Optimized Tryptase Substrate (Tryptase v. Factor Xa v. Human thrombin)



Units

Fluorometric Tryptase Activity Assay Using Ac-PRNK-ACC in Spiked Assay Buffer






FIG. 7




FIG. 8

Effects on Ac-PRNK-ACC based Tryptase Activity Assay Exogenously Added Protease Inhibitors:




FIG. 9

Aprotonin Treated, Tryptase Standard Curves (Serum v. Buffer)




FIG. 10

Tryptase Quantitation in Urine (Aprotonin Treated v. Uninhibited Samples)




FIG. 11

Enzymatic Inhibition of recombinant human β -I tryptase




FIG. 12

Enzymatic Inhibition of recombinant human β-II tryptase by PRNK-CMK




FIG. 13

Enzymatic Inhibition of Factor Xa by PRNK-CMK




FIG. 14